Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.

Abstract

The largest number of antidepressant treatment trials in premenstrual syndrome and premenstrual dysphoric disorder (PMDD) have been conducted with fluoxetine. Fluoxetine and other selective serotonin re-uptake inhibitors (SSRIs) clearly reduce premenstrual emotional and physical symptoms and improve premenstrual psychosocial functioning. Fluoxetine was the first SSRI to be approved by the FDA as a treatment for the emotional and physical symptoms of PMDD. Fluoxetine 20 mg has been reported to be effective for emotional and physical premenstrual symptoms with continuous daily dosing (every day of the menstrual cycle) and with luteal phase daily dosing (from ovulation to menses). In addition, premenstrual emotional symptoms have been reported to improve with fluoxetine 10 mg in luteal phase daily dosing and with 90 mg 2 and 1 weeks prior to menses. Fluoxetine is generally a well-tolerated treatment for PMDD and discontinuation effects have not been reported with intermittent dosing regimens.

• Authors: Teri Pearlstein, Kimberly A Yonkers
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 3 Issue 7 Pg. 979-91 (Jul 2002) ISSN: 1465-6566 [Print] England
• PMID: 12083997 (Publication Type: Journal Article, Review)

Chemical References

• Antidepressive Agents
• Serotonin Uptake Inhibitors
• Fluoxetine

Topics

• Antidepressive Agents (adverse effects, economics, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Administration Schedule
• Drug Interactions
• Female
• Fluoxetine (adverse effects, economics, pharmacology, therapeutic use)
• Humans
• Pregnancy
• Premenstrual Syndrome (drug therapy)
• Selective Serotonin Reuptake Inhibitors (adverse effects, economics, pharmacology, therapeutic use)
• Time Factors
• Treatment Outcome